1. Bosch FX, Manos MM, Munoz N, et al, and the International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
2. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382-2390.
3. Iftner T, Villa LL. Human papillomavirus technologies. J Natl Cancer Inst Monogr. 2003;31:80-88.
4. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
5. Schiffman M, Wheeler CM, Castle PE. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J Infect Dis. 2002;186:1169-1172.